LONDON, March 2, 2016 /PRNewswire/ --
The highly innovative UK based medical device company Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, is seeking to widen its network of global distribution partners to extend the roll-out of the geko™ device, designed to increase blood flow for in-hospital DVT prevention, within focus markets. A serious medical condition, DVT causes the formation of blood clots in a patient’s lower limb and the potential side effect of a pulmonary embolism (PE) which claims 544,000 EU and 300,000 USA lives annually[1] .
Firstkind is seeking to partner with distributors experienced in driving in-hospital adoption of new innovation with front-line staff. The geko™ device is evidence based, CE Mark certified, has NICE guidance (MTG19) recommending its use to the NHS for DVT prevention, US FDA clearance for USA market entry, regulatory approvals for entry into focus EU and middle east countries (with local language IFUs) and a geko™ device user training programme that is accredited by the Royal College of Nursing (RCN) for DVT prophylaxis.
Bernard Ross, CEO Firstkind says, “A key strategic aim for 2016 is the development of our global distribution footprint through long-term mutually beneficial partnerships for market entry into focus application areas and countries. The focus countries include: Belgium, Czech Republic, Denmark, Finland, France, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Saudi Arabia & UAE, South Africa, Spain, Sweden, Switzerland and USA. Partnering with Firstkind will provide distributors with the means to gain new revenue opportunities, backed by a best-in-class distributor support program, and the shared aim to improve clinical outcomes, patient care and to save health system resources. Interest via this email will receive our immediate attention: geko.support@firstkindmedical.com.”
A neuromuscular electrostimulation device, the geko™ gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, increasing venous, arterial and microcirculatory blood flow. The increase in blood flow is similar to that achieved by walking, up to 60%, without a patient having to move or exert energy. Worn at the knee, the battery powered geko™ device has no wires or leads, weighs just 10g, is easy and quick to fit and is silent in operation.
Originally created for the prevention of venous thromboembolism (VTE), the geko™ device is also CE Marked for the prevention and treatment of oedema, which can impair surgical wound healing and the treatment of lower limb chronic wounds.
About Firstkind and Sky Medical Technology Ltd
Sky Medical Technology, the parent of Firstkind Ltd, is a highly innovative UK based medical devices company that has developed a ground-breaking neuromuscular electrostimulation technology platform, OnPulse®. The company develops a range of products tailored to the needs of different medical application areas selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include DVT prevention, reduction of oedema, wound healing, elite sport recovery, and continence. The goal in each clinical area is to improve clinical outcomes and patient care whilst saving health system resources.
Ref 1. International Society on Thrombosis and Haemostasis (ISTH) http://www.worldthrombosisday.org/issue/vte/
http://www.gekodevices.com
©2016 PR Newswire. All Rights Reserved.
